Törnquist K, Lamberg-Allardt C
Acta Endocrinol (Copenh). 1987 Jun;115(2):225-8. doi: 10.1530/acta.0.1150225.
Treatment of rats with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 0.05 microgram/kg per day for three days was without any effect on serum T3, T4 or TSH concentrations, whereas serum PRL increased (20.6 +/- 3.8 to 76.2 +/- 19.1 micrograms/l, mean +/- SEM, N = 7-8; P less than 0.01). Increased hypothalamic TRH levels (24.3 +/- 3.9 to 45.7 +/- 7.8 pmol/g wet weight; P less than 0.01) may indicate an effect of 1,25(OH)2D3 on hypothalamic TRH homeostasis. This effect could probably be due to an indirect action of 1,25(OH)2D3, mediated by the increased serum calcium (2.77 +/- 0.02 to 3.16 +/- 0.08 mmol/l, mean +/- SEM, N = 7-8; P less than 0.001). This assumption was, however, not tested. Neither the pituitary TSH nor PRL was affected. The treatment decreased the serum concentration of 25-hydroxyvitamin D3 (23.0 +/- 1.3 to 16.8 +/- 2.0 nmol/l, mean +/- SEM, N = 5-7; P less than 0.01) and of 24,25-dihydroxyvitamin D3 (3.2 +/- 0.3 to 2.1 +/- 0.1 nmol/l, mean +/- SEM, N = 3-5; P less than 0.05). The results show that in this experimental design, 1,25(OH)2D3 has no effect on basal hormone secretion from the pituitary-thyroid axis, and that 1,25(OH)2D3 decreases the synthesis of the vitamin D3 metabolites studied.
每天以0.05微克/千克的剂量给大鼠注射1,25 - 二羟基维生素D3（1,25(OH)2D3），持续三天，对血清T3、T4或TSH浓度没有任何影响，而血清催乳素（PRL）升高（从20.6±3.8微克/升升至76.2±19.1微克/升，均值±标准误，N = 7 - 8；P＜0.01）。下丘脑促甲状腺激素释放激素（TRH）水平升高（从24.3±3.9皮摩尔/克湿重升至45.7±7.8皮摩尔/克湿重；P＜0.01），这可能表明1,25(OH)2D3对下丘脑TRH的稳态有影响。这种影响可能是由于血清钙升高（从2.77±0.02毫摩尔/升升至3.16±0.08毫摩尔/升，均值±标准误，N = 7 - 8；P＜0.001）介导的1,25(OH)2D3的间接作用。然而，这一假设并未得到验证。垂体促甲状腺激素（TSH）和催乳素（PRL）均未受影响。该处理降低了血清25 - 羟基维生素D3（从23.0±1.3纳摩尔/升降至16.8±2.0纳摩尔/升，均值±标准误，N = 5 - 7；P＜0.01）和24,25 - 二羟基维生素D3（从3.2±0.3纳摩尔/升降至2.1±0.1纳摩尔/升，均值±标准误，N = 3 - 5；P＜0.05）的浓度。结果表明，在该实验设计中，1,25(OH)2D3对垂体 - 甲状腺轴的基础激素分泌没有影响，且1,25(OH)2D3会降低所研究的维生素D3代谢物的合成。
